Pharma BD Deal Intelligence
PowderMed's DNA/PMED vaccine platform vanished without a single approval, product, or later mention -- Pfizer's real flu-vaccine future came from an unrelated 2018 mRNA deal with BioNTech
Full analysis, sources & comparables →Pfizer's purchase of PowderMed for an estimated $400 million marks its first move into human vaccine technology, betting on DNA vaccines and needle-free…
PowderMed sits inside Pfizer's broader biologics push, but analysts note the lack of late-stage assets and question whether DNA vaccines can deliver near-term…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
DNA-based vaccines; particle-mediated epidermal delivery (PMED); estimated $400M, terms undisclosed
PowderMed's DNA/PMED vaccine platform vanished without a single approval, product, or later mention -- Pfizer's real flu-vaccine future came from an unrelated 2018 mRNA deal with BioNTech
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / PowderMed Ltd. (this deal) | 2006 | $400M | 14 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2006 deals · Pfizer Inc. deals